Abstract:Hongmei Yang, 1, &ast Zhongqi Liu, 1, &ast Fan Liu, 1, 2, &ast Haixuan Wu, 1 Xiaoyan Huang, 1 Rong Huang, 1 Phei Er Saw, 3, 4 Minghui Cao 1, 2 1 Department of Anesthesiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China; 2 Department of Anesthesiology, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516600, People's Republic of China; 3 Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China; 4 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China &astThese authors contributed equally to this work Correspondence: Phei Er Saw; Minghui Cao, Email ; Background: Opioids are irreplaceable analgesics owing to the lack of alternative analgesics that offer opioid-like pain relief. However, opioids have many undesirable central side effects. Restricting opioids to peripheral opioid receptors could reduce those effects while maintaining analgesia. Methods: To achieve this goal, we developed Tet1-LNP (morphine), a neural-targeting lipid nanoparticle encapsulating morphine that could specifically activate the peripheral opioid receptor in the dorsal root ganglion (DRG) and significantly reduce the side effects caused by the activation of opioid receptors in the brain. Tet1-LNP (morphine) were successfully prepared using the thin-film hydration method. In vitro, Tet1-LNP (morphine) uptake was assessed in differentiated neuron-like PC-12 cells and dorsal root ganglion (DRG) primary cells. The uptake of Tet1-LNP (morphine) in the DRGs and the brain was assessed in vivo. Von Frey filament and Hargreaves tests were used to assess the antinociception of Tet1-LNP (morphine) in the chronic constriction injury (CCI) neuropathic pain model. Morphine concentration in blood and brain were evaluated using ELISA. Results: Tet1-LNP (morphine) had an average size of 131 nm. Tet1-LNP (morphine) showed high cellular uptake and targeted DRG in vitro. CCI mice treated with Tet1-LNP (morphine) experienced prolonged analgesia for nearly 32 h compared with 3 h with free morphine ( p < 0.0001). Notably, the brain morphine concentration in the Tet1-LNP (morphine) group was eight-fold lower than that in the morphine group ( p < 0.0001). Conclusion: Our study presents a targeted lipid nanoparticle system for peripheral neural delivery of morphine. We anticipate Tet1-LNP (morphine) will offer a safe formulation for chronic neuropathic pain treatment, and promise further development for clinical applications. Keywords: lipid nanoparticle, Tet1, peripheral nerve-targeted, pain management, chronic neuropathic pain Opioids remain the mainstay of analgesic treatment for perioperative, severe, acute, and chronic pain. However, opioid clinical effectiveness is restricted due to adverse side effects that are mainly caused by activating the μ-opioid receptors in the central nervous system (CNS), 1 including sedation, apnea, tolerance, and addiction which lead to an epidemic of overdoses, death, and abuse. 2 Therefore, there is an urgent need to develop novel therapeutic strategies for the management of pain. Currently, various approaches are being explored, including focusing on μ-opioid receptor (MOR) splice variants, generating biased agonists, or targeting other receptors such as heteromers with MOR. 3 Despite significant advances, clinical translation of these strategies remains challenging. Researchers have reduced opioid side effects by regulating transient receptor potential vanilloid 1 (TRPV1) receptors. 4 However, TRPV1 antagonists may increase the thermal pain threshold in humans, potentially increasing the risk of burn injury. 5 As central effects account for the majority of opioid-related adverse effects, the use of opioid receptors only in peripheral sensory neurons is a promising therapeutic strategy to limit central adverse effects while maintaining analgesic effects. 3 There is growing evidence that peripheral sensory neurons mediate antinociceptive effects. 6,7 Primary sensory neurons, with cell bodies within dorsal root ganglia (DRGs), project fibers to the peripheral terminals of sensory neurons 8 and opioid receptors exist in DRG neurons of different diameters and prototypical sensory neuropeptides. 9 When there is a pain signal, opioid recep -Abstract Truncated-

Action of Β-Endorphin and Nonsteroidal Anti-Inflammatory Drugs, and the Possible Effects of Nonsteroidal Anti-Inflammatory Drugs on Β-Endorphin.

Effect of non-steroidal anti-inflammatory drugs used for analgesia on plasma β-endorphin -A Meta-analysis

The Role of Opioid in the Mechanism of the Hypotensive Effect by Simulating Acupuncture on Rat Hindlimb

Inhibition of the N-methyl-d-aspartate receptor unmasks the antinociception of endogenous opioids in the periphery

[Recent findings in biochemistry and the significance of endorphins and enkephalins]

Involvement of Endogenous Beta-Endorphin in Antinociception in the Arcuate Nucleus of Hypothalamus in Rats with Inflammation

β-Endorphin in vitro inhibition of striatal dopamine release

Investigating beta-endorphins: ways to boost health, conventional and future detection methods

The Spinal Antinociceptive Effects of Endomorphins in Rats: Behavioral and G Protein Functional Studies

Bifunctional opioid and <sub>1</sub> receptor ligands as novel analgesics with reduced side effects

Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

Preemptive intrathecal administration of endomorphins relieves inflammatory pain in male mice via inhibition of p38 MAPK signaling and regulation of inflammatory cytokines

Possible mechanism and potential application of anti-opioid effect of diazepam-binding inhibitor

Comparison of Morphine and Endomorphin Analog ZH853 for Tolerance and Immunomodulation in a Rat Model of Neuropathic Pain

The impact of multifunctional enkephalin analogs and morphine on the protein changes in crude membrane fractions isolated from the rat brain cortex and hippocampus

Contribution of the μ opioid receptor and enkephalin to the antinociceptive actions of endomorphin-1 analogs with unnatural amino acid modifications in the spinal cord

Effects of Brain-Derived Neurotrophic Factor and Adeno-Associated Viral Vector on Morphine-Induced Condition Through Target Concentration Changes in the Ventral Tegmental Area and Nucleus Accumbens

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies

TET1-Lipid Nanoparticle Encapsulating Morphine for Specific Targeting of Peripheral Nerve for Pain Alleviation

Morphine Activates Neuroinflammation In A Manner Parallel To Endotoxin